References
- Boopathy S, Silvas TV, Tischbein M, et al. Structural basis for mutation-induced destabilization of profilin 1 in ALS. Proc Natl Acad Sci USA. 2015;112:7984–9.
- Kwiatkowski TJ Jr., Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–8.
References
- Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018;217(1):51–63.
- Nedelsky NB, Taylor JP. Bridging biophysics and neurology: aberrant phase transitions in neurodegenerative disease. Nat Rev Neurol. 2019;15(5):272–86.
- Ganassi M, Mateju J, Bigi I, et al. A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism. Mol Cell. 2016;63(5):796–810.
- Marrone L, Poser I, Casci I, et al. Isogenic FUS-eGFP iPSC reporter lines enable quantification of FUS stress granule pathology that is rescued by drugs inducing autophagy. Stem Cell Rep. 2018;10(2):375–89.
- Mediani L, Guillen-Boixet J, Vinet J, et al. Defective ribosomal products challenge nuclear function by impairing nuclear condensate dynamics and immobilizing ubiquitin. EMBOJ. 2019:e101341.
- Lee KH, Zhang P, Kim HJ, et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167(3):774–88.
- Brandman O, Hegde RS. Ribosome-associated protein quality control. Nat Struct Mol Biol. 2016;23(1):7–15.
References
- Milinis K, Tennant A, Mills RJ, et al. Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis. Acta Neurol Scand. 2018;138:47–54.
- Rasch G. Probabilistic models for some intelligence and attainment tests. Chicago: University of Chicago Press; 1980.
References
- Bergsma T, Rogaeva E. DNA methylation clocks and their predictive capacity for aging phenotypes and healthspan. Neurosci Insights. 2020;15:2633105520942221.
- Zhang M, McKeever PM, Xi Z, et al. DNA methylation age acceleration is associated with ALS age of onset and survival. Acta Neuropathol. 2020;139(5):943–6.
References
- Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14:9–21.
- Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307–21.
- Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New Engl J Med. 2017;377:1723–32.
- Mercuri E, Darras BT, Chiriboag CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. New Engl J Med. 2018;378:625–35.
- Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383:109–19.
References
- Abrahao A, Meng Y, Llinas M et al. First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat Commun. 2019;10(1):4373.
- Meng Y, Abrahao A, Heyn CC, et al. Glymphatics visualization after focused ultrasound‐induced blood–brain barrier opening in humans. Ann Neurol. 2019;86(6):975–80.
Reference
- Schmahmann JD, Guell X, Stoodley CJ, et al. The theory and neuroscience of cerebellar cognition. Annu Rev Neurosci. 2019;42:337–64.